NanoViricides, Inc. Announces Symbol Change, Schedule for Filing.

MIAMI -- NanoViricides, Inc. (Pink Sheets:NNVC), announced the change of its name from Edot-com.com, Inc. and stock symbol from ECMM to NNVC, effective July 5, 2005. "This change completes phase one of our entry into the public marketplace," stated Eugene Seymour, CEO of NanoViricides, "now our shareholders can identify our company by name."

"Shortly, we hope to have completed and filed a Form 10-SB, commencing our status as a fully-reporting company with the Securities and Exchange Commission," added Seymour. "We are working with our new auditors to complete all financial reports required for compliance in the hope that our securities may be quoted on the OTC Bulletin Board, and ultimately, listed on a national exchange. Our shareholders require the greater liquidity and market support that the bulletin board system affords buyers and sellers of our shares. We are excited at the milestones before us and proud of our achievements to date."

NanoViricides, Inc.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that in 2006, it will license the products to major pharmaceutical companies.

Forward-Looking Statements

Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of our products and services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management or increased government regulation.